TNGX Q4 2022 Earnings — Tango Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TNGXTango Therapeutics, Inc.

$2B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M+12.2% YoY

Gross Profit

$5M77.4% margin

Operating Income

-$31M-476.8% margin

Net Income

-$29M-453.3% margin

EPS (Diluted)

$-0.33

QoQ Revenue Growth

-7.4%

Cash Flow

Operating Cash Flow

-$28M

Free Cash Flow

-$29M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$436M

Total Liabilities

$187M

Stockholders' Equity

$249M

Cash & Equivalents

$60M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$6M	+12.2%
Gross Profit	$5M	$5M	-3.5%
Operating Income	-$31M	-$22M	-39.0%
Net Income	-$29M	-$22M	-31.8%

Revenue Segments

Collaboration Revenue

$6M100%